Hennessy, M. A., Gatsonis, C., Jacene, H., Connolly, R. M., Burnette, B. L., Stringer-Reasor, E. M., Romanoff, J., Taurone, A., O'Sullivan, C. C., Le-Petross, H. T., Stearns, V., Fowler, A. M., Tang, S., Sepulveda, K. A., DeMichele, A. M., Mankoff, D. A., Wolff, A. C. EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial) , Future Oncology : 2025
DeMichele, A., Clark, A. S., Shea, E., Bayne, E. J., Sterner, C. J., Rohn, K., Dwyer, S., Pan, T., Nivar, I., Chen, Y., Wileyto, P., Berry, L. R., Deluca, S., Savage, J., Makhlin, I., Pant, D. K., Martin, H., Egunsola, A., Mears, N., Goodspeed, B. L., Chislock, E. M., Graves, J., Wang, J., Shih, N., Belka, G. K., Berry, D., Nayak, A., Feldman, M., & Chodosh, L. A. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial
, Nature Medicine: 2025
Gerratana L, Reduzzi C, Ren Y, Jeselsohn R, Mahtani RL, Ma CX, DeMichele A, Meisel JL, Miller K, Abdou Y, Riley EC, Qamar R, Sharma P, Reid SA, Ko N, Liu Y, Gauthier E, Burstein HJ, DeMeo M, Tolaney SM, Regan MM, Cristofanilli M, Mayer EL. Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study. , Clin Cancer Res: 2025
Van Hassel J, Dimitroff K, Yau C, Mukhtar R, Boughey JC, Ladores V, Howard-McNatt MM, Jaskowiak N, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Veer LV, Rugo H, Esserman LJ, Shatsky R, Isaacs C, Kuerer H, Wallace AM, Prionas N, Tseng J, Reyna CR, Taunk N, Kesmodel S, Lee MC, Fox J, Piltin MA, Tchou J, Arciero CA, Postlewait LM, Sauder C, Rao R. Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial , Ann Surg Oncol.: 2025
Mukhtar, R. A., Dimitroff, K., Yau, C., Chien, A. J., Connolly, E. P., Howard-McNatt, M., Rao, R., Ladores, V., Golshan, M., Sauder, C. A., Ahmed, K., Lancaster, R., Fox, J., Gutnik, L., Lee, M. C., Tchou, J., Prionas, N., Arciero, C. A., Reyna, C., Kuerer, H., Switalla, K., Taunk, N., Tuttle, T. M., Moran, M. S., Postlewait, L. M., Perlmutter, J., DeMichele, A., Yee, D., Hylton, N., Symmans, W. F., Rugo, H. S., Shatsky, R., Isaacs, C., Esserman, L. J., Van't Veer, L., Boughey, J. C. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial , Annals of surgical oncology: 2025
Villacampa, G., Pascual, T., Tarantino, P., Cortés, J., Perez-García, J., Llombart-Cussac, A., Conte, P., Mancino, M., Guarneri, V., Dieci, M. V., Waks, A. G., Schettini, F., Brasó-Maristany, F., Griguolo, G., de Castro, B. A., Reboredo, C., Antolín, S., Bueno-Muiño, C., Echavarría, I., López-Tarruella, S., Massarrah, T., Monte-Millán, M. D., Martin, M., Buckingham, W., Parker, J. S., Vivancos, A., Polyak, K., Filho, O. M., Wolff, A. C., DeMichele, A., Tung, N. M., Perou, C. M., Paré, L., Villagrasa, P., Prat, A., Tolaney, S. M. HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
, Lancet Oncology: 2025
Kaur, M., Dimitroff, K., Boughey, J. C., Esserman, L. J., Yau, C., Tchou, J., Quirarte, A., Lee, M. C., Howard-McNatt, M. M., Switalla, K., Kuerer, H., Sauder, C., Postlewait, L. M., Arciero, C., Rao, R., Wallace, A., Reyna, C., Ahmed, K., Gutnik, L., Taunk, N., Perlmutter, J., DeMichele, A., Yee, D., Yee, D., Hylton, N., Symmans, W. F., Rugo, H. S., Shatsky, R., Isaacs, C., Rudra, S., Pohlmann, P., Ewing, C., Wong, J., Alvarado, M., Jaskowiak, N., Prionas, N., Golshan, M., Piltin, M. A., Olopade, O. I., Mukhtar, R. A. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial
, Ann Surg Oncol : 2025
Shinn, E., Zahrieh, D., DeMichele, A., Zdenkowski, N., Lemieux, J., Mao, J., Bjelic-Radisic, V., Naughton, M. J., Pfeiler, G., Gelmon, K., Balko, J. M., Egle, D., Zoppoli, G., Traina, T., Jimenez, M. M., Novoa, S. A., Haddad, T., Chan, A., Ring, A., Wolff, A., Symanns, W. F., Lorenzo, J. P., Sabanatha, D., Burstein. H. J., Bellet-Ezquerra, M., Foukakis, T., Novik, Y., Rubovszky, G., Singer, C. F., Muehlbacher, K., Filho, O. M., Goulioti, T., Law, E., Partridge, A. H., Carey, L. A., Zoroufy, A., Hlauschek, D., Fesl, C., Mayer, E. L., Gnant, M. Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer , Breast Cancer Res Treat: 2025
Wolf, D. M., Yau, C., Campbell, M., Glas, A., Barcaru, A., Mittempergher, L., Kuilman, M., Brown-Swigart, L., Hirst, G., Basu, A., Magbanua, M., Sayaman, R., Huppert, L., Delson, A., I-SPY2 Investigators, Symmans, W. F., Borowsky, A., Pohlmann, P., Rugo, H., Clark, A., Yee, D., DeMichele, A., Perlmutter, J., Petricoin, E. F., Chein, J., Stringer-Reasor, E., Shatsky, R., Liu, M., Han, H., Soliman, H., Isaacs, C., Nanda, R., Hylton, N., Pusztai, L., Esserman, L., van 't Veer, L. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
, JCO Precis Oncol: 2025
Hahnen, E., Hauke, J., Gelmon, K., Marmé, F., Ernst, C., Martin, M., Untch, M., Bonnefoi, H., Knudsen, E., Im, S.-A., DeMichele, A., Van’t Veer, L., Kim, S.-B., Bear, H., McCarthy, N., Rhiem, K., Turner, N., Witkiewicz, A., Rojo, F., Filipits, M., Martin, LA., Fasching, P. A., Schem, C., Becker, K., García-Sáenz, J. A., Kelly, C. M., Reimer, T., Toi, M., Rugo, H. S., Denkert, C., Gnant, M., Makris, A., Liu, Y., Valota, O., Felder, B., Weber, K., Nekljudova, V., Loibl, S. BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis , JCO Precision Oncology: 2025
